TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: STEM-PD Open Label Extension (OLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of the study activities in the STEM-PD RCT trial. l.~* Participants must be willing and able to give consent to participate in the study trial.~Exclusion Criteria:~* Participant anticipates being unable to attend all visits and complete all study activities in both the RCT and OLE study trial.~* Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the RCT or OLE study trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Treatment 1 (Type: EXPERIMENTAL): Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Group 1 :~* Patient over 18 years old,~* Patient informed and not opposed to participate~* Patient followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis)~* Treatment with immunosuppressant and / or immunomodulator~* Group 2 :~* Patient over 18 years old,~* Patient informed and not opposed to participate~* Patient not followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis)~* Absence of treatment with immunosuppressant and / or immunomodulator~Exclusion Criteria:~* Contraindication to vaccination~* Progressive cancer~* Pregnant or breastfeeding woman~* Current infection less than 3 weeks old~* Weight less than 40 kg~* Patient under tutor- or curator-ship~* Patient without health insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with auto-immune or autoinflammatory diseases (Type: None): Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics
- Patients without auto-immune or autoinflammatory diseases (Type: None): Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who present to the emergency department (ED) with isolated femur fracture (no other injuries)~* Patients who are cognitively alert and are able to verbalize their pain using a visual analog scale (VAS)~* Patients who are mentally competent to consent for the study~* Patients who can communicate in English or Spanish~Exclusion Criteria:~* Gestation~* Prisoners~* Patients who cannot communicate in English or in Spanish~* Patients who have other significant injuries besides a femur fracture~* Patients who are cognitively impaired and/or unable to verbalize their pain using a visual analog scale (VAS)~* Patients with allergies to local anesthetics~* Patients with severe liver disease~* Patients with existing peripheral neuropathies in the affected limb~* Patients with history of complications from previous femoral blocks~* Patients with contraindications for needle insertion at inguinal area~* Local signs of infection~* Patient on anticoagulants and/or with history of coagulation disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Echogenic needle (Type: EXPERIMENTAL): The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
- Standard of care needle (Type: ACTIVE_COMPARATOR): The control group will receive ultrasound-guided femoral nerve block using standard of care needles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effectiveness of Cardiac Rehabilitation (Rehab) for Acute Decompensated Heart Failure Patients on 6 Minute Walk Test and Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Admitted with acute, decompensated heart failure~* Signed informed consent~Exclusion Criteria:~* Approved by Center for Medicare and Medicaid Services (CMS) to enroll in cardiac rehab~* Have an elective procedure that would interrupt their exercise program~* Unable to partake in an exercise program due to physical incapacities~* Pregnancy~* Unable to read and understand the consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: NO_INTERVENTION): This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
- Cardiac rehab (Type: EXPERIMENTAL): This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-65 years of age;~* HBeAg negative chronic hepatitis B;~* treated with lamivudine for \>=6 months;~* demonstrated lamivudine resistance;~* compensated liver disease.~Exclusion Criteria:~* severe hepatic dysfunction;~* previous treatment with antivirals other than lamivudine;~* immunosuppressant treatment in past 6 months;~* co-infection with hepatitis A, C, or D virus or human immunodeficiency virus;~* medical condition associated with chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatient adult males and females who are at least 18-89 years of age, undergoing treatment with antibiotics irrespective of indication and the type of antibiotics.~Exclusion Criteria:~* Diarrhea on admission or within the preceding week~* Reported recurrent diarrhea~* Bowel pathology that could result in diarrhea (including preexisting Inflammatory Bowel disease{IBD}, all forms for colitis or any other condition resulting in preexisting diarrhea)~* Intake of high risk antibiotics (clindamycin, cephalosporins, aminopenicillins→ well known to cause CDAD) and or more than two courses of other antibiotics in the past four weeks to exclude pre-existing diarrhea associated with antibiotic use~* Immunosuppression (Chronic steroid use, Active chemotherapy, Active radiotherapy, HIV or any other disorder resulting in a compromise in participants immune status)~* Bowel surgery causing liquid stools~* Regular probiotic intake before admission~* Lactose intolerance or intolerance to dairy products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules
- Probiotics (Type: EXPERIMENTAL): Lactobacillus Rhamnosus GG 10 billion cfu BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of HCO1100 on Cardiovascular Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Dialysis dependent chronic renal failure (CKD 5) in a stable condition~* Serum albumin at randomisation equal to or above the median of the normal range (pre- dialysis value)~Exclusion Criteria:~* Diabetes mellitus as the disease underlined end stage renal failure~* Haemodynamic instability that precludes unsupported dialysis~* planned surgical interventions \<= 4 months at time of inclusion~* known allergy against dialysis membranes~* Significant cardiac disease (atrial fibrillation, myocardial infarction within 6 months; unstable angina pectoris; LV-EF \< 30%, clinically significant pericardial disease; cardiac amyloidosis)~* pulmonary disease with chronic hypoxia~* Advanced disease or significant co-morbidity with poor short term prognosis, necessitating palliation and not subject to active or disease specific treatment~* Clinically significant liver dysfunction (bilirubin \> 1.8mg/dl (30µmol/L))~* Prior fistula surgery on both arms or other operations or paralysis on both arms~* Known HIV, HCV infection~* Alcoholism~* Active uncontrolled infection~* Pregnancy or lactation~* Inability to give informed consent to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dialysis treatment with HCO1100 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: First in Man Study of the JenaValve TAVI Plus System Transfemoral

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with severe native aortic valve stenosis~* NYHA functional class II or higher~* Increased risk for surgical aortic valve replacement~* Comply with post-operative follow-up visits and requirements~Exclusion Criteria:~* Combined aortic valve disease with severe aortic insufficiency~* Presence of moderate mitral insufficiency or previous mitral prosthesis~* Severe pulmonary hypertension~* Congenital uni- or bicuspid aortic valve~* Endocarditis or active infection~* Life expectancy \< 12 months~* Need for emergency surgery for any reason

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcatheter Aortic Valve Replacement (Type: EXPERIMENTAL): In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Nuts in Obese Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* obese subjects (BMI ≥ 95th percentile for age and sex; reference tables for WHO BMI);~* Aged between 6 and 17 years;~* Signature applied in the informed consent by both parents and consent of the child~Exclusion Criteria:~* chronic liver diseases (hepatitis, cirrhosis).~* Chronic renal failure (serum creatinine\> 1.2 mg / dL).~* Malignancies.~* Diabetes (fasting blood glucose ≥ 126 mg / dl or therapy with oral hypoglycemic drugs or insulin).~* cholesterol-lowering or antihypertensive terapy.~* Notes allergies to nuts or hazelnuts or food intolerance to nuts and/or hazelnuts.~* Treatment of less than 6 weeks with any medication which can interfere with fecal microbiota (particularly antibiotics or laxatives).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- wNUTS, low-caloric diet plus nuts (Type: EXPERIMENTAL): low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
- w/oNUTS, low-caloric diet without nuts (Type: OTHER): low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Between the ages of 6-17 at the time of study participation.~* Have a diagnosis of any malignancy that required CNS treatment such as surgery and/or irradiation and/or intrathecal chemotherapy. (Patients treated with systemic chemotherapy alone are not eligible to participate)~* Off treatment and cancer free for a minimum of 6 months.~* Have a proficiency in English.~EXCLUSION CRITERIA:~* Patients with an estimated intelligence quotient (IQ) of less than 65 (based on the Wide Range Achievement Test (WRAT-3) Reading subtest) are not eligible to continue on study.~* At least one standard deviation below the level of performance predicted by their IQ on at least 2 of the 3 WISC-III subtests.~* Diagnosed with Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) prior to their cancer diagnosis.~* Currently taking antidepressants, antipsychotics, or other stimulants.~* Are blind.~* Have glaucoma.~* Family history of motor and phonic tics or Tourette's syndrome.~* Have seizures not controlled by antiepileptic drugs. (Note: Patients who are not experiencing seizure activity, having been on a stable dose of an antiepileptic drug for at least 12 weeks may participate)~* Taking a monoamine oxidase (MAO) inhibitor.~* Have a history of cardiovascular disease, uncontrolled hypertension or hyperthyroidism.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1- Adderall- XR® (Type: EXPERIMENTAL): Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
- Arm II Concerta® (Type: EXPERIMENTAL): Concerta ® 18 mg/day for 3-12 weeks depending on subject's response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Moxifloxacin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with TB, with Mycobacterium tuberculosis (or M. africanum) by culture~* Starting treatment with MFX in a dose of 400 mg as part of their TB treatment~Exclusion Criteria:~* Contra-indication for MFX~* Baseline QTc-interval \> 450 msec~* History of resuscitation~* History of ventricular tachycardia (including Torsades de Pointes)~* Family history of sudden cardiac death or Torsades de Pointes~* Additional risk factors for Torsades de Pointes (including known heart failure, Left ventricular hypertrophy)~* Use of concomitant treatment with QT/QTc prolonging drugs (including anti-dysrhythmics class IA and III, antipsychotics, tricyclic antidepressants or the antihistaminic drug terfenadine)~* Abnormal electrolytes (K, Mg, Na, Ca)~* Abnormal cardiac repolarisation on screening/baseline ECG~* History of adverse events to fluoroquinolones~* HIV co-infection~* RIF treatment during last 3 weeks before start of the study. After a washout period of 3 weeks the patient can be included.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: EXPERIMENTAL): Moxifloxacinin escalating dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer~* HbA1c \<5.7%~Exclusion Criteria:~* Previous treatment for advanced disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CP-751,871 + exemestane Treatment until progression or toxicity
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: First-time Fathers' Experiences of Childbirth in Lorraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First time father after a physiological pregnancy and delivery of a healthy newborn of more than 37 gestational weeks.~Exclusion Criteria:~-

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Type I maternity (Type: None): Fathers who experienced a first childbirth in a type I maternity in Lorraine.
- Type II maternity (Type: None): Fathers who experienced a first childbirth in a type II maternity in Lorraine.
- Type III maternity (Type: None): Fathers who experienced a first childbirth in a type III maternity in Lorraine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients \>18 years old~2. Able to provide informed consent, or presence of a legally authorized representative~3. Meets criteria for operative management as below (Table 1).~Table 1. Criteria for FCDC (criteria A, B and C all need to be met)~A. A diagnosis of FCDC as determined by a history consistent with C.Difficile infection and one of the following:~1. A positive toxin assay~2. Endoscopic finding of pseudomembranes~3. CT scan findings of pancolitis~B. At least 2 of the following:~1. Worsening abdominal distention or abdominal pain~2. Sepsis: 2 of the following (HR\>100bpm, MAP\<60mmHg, temperature\>38.5C or\<36.5C, and fluid requirement \>2L)~3. New onset ventilatory requirement~4. Vasopressor requirement~5. Mental status changes~6. Unexplained clinical deterioration~7. Stable elevated leukocytosis or leukopenia, or worsening leukocytosis, defined as \>20,000 or \<3,000x109/L~C. Attending physician of record (ICU or medicine/surgery) is in agreement with an operative approach~-~Exclusion Criteria:~1. Children (\<18 years old)~2. Allergy to vancomycin or polyethyleneglycol~3. Colonic perforation or necrosis~4. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Loop ileostomy with colonic lavage (Type: EXPERIMENTAL): creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
- Total abdominal colectomy with end ileostomy (Type: ACTIVE_COMPARATOR): Removal of entire colon with preservation of rectal stump and construction of end ileostomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues